Albany Molecular Research, Inc. (AMRI) recently appointed Subramanyam Maddala as the president, India Operations. Maddala assumes leadership for AMRI's Indian API manufacturing operations as well as responsibility for AMRI facility operations in Hyderabad and Aurangabad, India.
Along with the appointment of Maddala, AMRI informed that Dr Rajesh Shenoy, managing director, AMRI India will be relocating back to the United States to assume the position of director, project management-pharmaceutical services, continuing to report to Dr Hagen. Dr Shenoy will have full leadership responsibilities for AMRI's global project management activities throughout the pharmaceutical services sector, including small scale, large scale, GMP activities, formulations development and manufacturing, and sterile fill and finish.
Maddala who brings more than 20 years of operations, business development, and senior leadership experience in the manufacturing of APIs and intermediates, custom synthesis, and formulations in branded and generics markets will be reporting to Dr Steven Hagen, vice president of pharmaceutical development and manufacturing at AMRI.
Most recently, he served as vice president, Contract Research and Manufacturing Services (CRAMS) and New Generics for Shasun Pharmaceuticals, and was responsible for Shasun's contract research and manufacturing business, including all vertical CRAMs businesses and new API generic efforts. Prior to that, Maddala held several roles of increasing responsibility at firms like Piramal India, Glenmark Pharmaceuticals, Medicorp/Matrix Labs, Torrent Pharmaceuticals, SOL and Lupin Laboratories.
Maddala earned a Master of Science degree in Applied Chemistry from the University of Baroda, India and a Bachelor of Science degree in Chemistry from Osmania University in Hyderabad, India.